Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK216 in Relapsed or Refractory Ewing Sarcoma
NCT02657005Phase 2Terminated
- Sponsor
- Oncternal Therapeutics
- Start
- Aug 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TK216 in Ewing sarcoma, sponsored by Oncternal Therapeutics. Started Aug 2016; status: terminated.
02
Drugs
TK216
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT02657005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657005.